These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33545846)

  • 1. Nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles: Evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis.
    Tosyali OA; Allahverdiyev A; Bagirova M; Abamor ES; Aydogdu M; Dinparvar S; Acar T; Mustafaeva Z; Derman S
    Mater Sci Eng C Mater Biol Appl; 2021 Jan; 120():111684. PubMed ID: 33545846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of recombinant Omp25 or EipB protein loaded PLGA nanovaccines for Brucellosis protection.
    Akmayan I; Oztav S; Coksu I; Abamor ES; Acar S; Ozbek T
    Nanotechnology; 2024 Jul; 35(39):. PubMed ID: 38917779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation.
    Katebi A; Varshochian R; Riazi-Rad F; Ganjalikhani-Hakemi M; Ajdary S
    Biomed Pharmacother; 2021 May; 137():111276. PubMed ID: 33485119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.
    Agallou M; Margaroni M; Athanasiou E; Toubanaki DK; Kontonikola K; Karidi K; Kammona O; Kiparissides C; Karagouni E
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005311. PubMed ID: 28114333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
    Hojatizade M; Soleymani M; Tafaghodi M; Badiee A; Chavoshian O; Jaafari MR
    Iran J Immunol; 2018 Dec; 15(4):281-293. PubMed ID: 30593742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with Leishmania mexicana LPG induces PD-1 in CD8⁺ and PD-L2 in macrophages thereby suppressing the immune response: a model to assess vaccine efficacy.
    Martínez Salazar MB; Delgado Domínguez J; Silva Estrada J; González Bonilla C; Becker I
    Vaccine; 2014 Mar; 32(11):1259-65. PubMed ID: 24462405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new approach for development of vaccine against visceral leishmaniasis: Lipophosphoglycan and polyacrylic acid conjugates.
    Allahverdiyev AM; Cakir Koc R; Bagirova M; Elcicek S; Baydar SY; Oztel ON; Abamor ES; Ates SC; Topuzogullari M; Isoglu Dincer S; Akdeste Z
    Asian Pac J Trop Med; 2017 Sep; 10(9):877-886. PubMed ID: 29080616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two biochemically distinct lipophosphoglycans from Leishmania braziliensis and Leishmania infantum trigger different innate immune responses in murine macrophages.
    Ibraim IC; de Assis RR; Pessoa NL; Campos MA; Melo MN; Turco SJ; Soares RP
    Parasit Vectors; 2013 Mar; 6():54. PubMed ID: 23497381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
    Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
    Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses.
    Srivastava S; Pandey SP; Jha MK; Chandel HS; Saha B
    Clin Exp Immunol; 2013 Jun; 172(3):403-9. PubMed ID: 23600828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):84-9. PubMed ID: 11682952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
    Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
    Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB/c mice.
    Katebi A; Riazi-Rad F; Varshochian R; Ajdary S
    Int Immunopharmacol; 2024 Jun; 138():112538. PubMed ID: 38924865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation.
    Mehravaran A; Jaafari MR; Jalali SA; Khamesipour A; Tafaghodi M; Hojatizade M; Abbasi A; Badiee A
    Iran J Immunol; 2015 Dec; 12(4):274-87. PubMed ID: 26714419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral pentamidine-loaded poly(d,l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment.
    Valle IV; Machado ME; Araújo CDCB; da Cunha-Junior EF; da Silva Pacheco J; Torres-Santos EC; da Silva LCRP; Cabral LM; do Carmo FA; Sathler PC
    Nanotechnology; 2019 Nov; 30(45):455102. PubMed ID: 31365912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania infantum-derived lipophosphoglycan as an antigen in the accurate serodiagnosis of canine leishmaniasis.
    Portela RD; Soares RP; Passos GP; Larangeira DF; Barral TD; Sampaio JR; Bernardo MF; Alves-Sobrinho EV; Bahia MT; Pinho FA; Barrouin-Melo SM
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007720. PubMed ID: 31513599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation.
    Margaroni M; Agallou M; Kontonikola K; Karidi K; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Eur J Pharm Biopharm; 2016 Aug; 105():18-31. PubMed ID: 27235727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.